Stephen Lim

Stephen Lim is the current CEO of FathomX. Stephen has also previously served as the CEO of BioCheetah Pte Ltd and as the General Manager of CMS Biotech Pte Ltd.

Lim has over 15 years of experience in the medical and biotech industries. Stephen started their career as a research scientist at Genentech, where they worked on developing monoclonal antibodies for cancer diagnostics. Stephen then transitioned into the commercial side of the industry, first as the CEO of BioCheetah Pte Ltd, a medical diagnostic start-up focused on cancer diagnostics, and then as the General Manager of CMS Biotech Pte Ltd, a subsidiary of China Medical System Holdings Ltd.

Under Lim's leadership, both BioCheetah and CMS Biotech have seen significant growth and success. At BioCheetah, they led the company to develop innovative products that were regional first-in-class or had the best efficacy, safety, or cost-effectiveness in their class. At CMS Biotech, they oversaw the company's expansion into the ASEAN market and developed a product pipeline with a high innovation level and competitive differentiation advantages.

Lim's experience and success in the medical and biotech industries make him well-suited to their current role as CEO of FathomX. Under their leadership, FathomX has continued to grow and innovate, developing new products and expanding into new markets.

Stephen Lim completed their Honours Degree in Economics from the National University of Singapore. Stephen also holds a certification from the National University of Singapore in LEAN SIX SIGMA FOUNDATION (YELLOW BELT). Prior to that, they attended Kim Keat Primary School.

Some direct reports include Henry Johnson - QA & RA Project Manager, Secondment, Anna Mannervik - Head of Public Affairs, and Mikael Hartman - Co-Founder & CMO.